Globally, several major pharma giants are thoroughly working toward developing new treatment therapies for Cholestatic Pruritus to provide better relief for the symptoms and hence improve the QoL of patients with Cholestasis.
DelveInsight’s “Cholestatic Pruritus Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cholestatic Pruritus market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Cholestatic Pruritus market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cholestatic Pruritus: An Overview
Cholestasis is defined as a decrease in bile flow due to the impaired secretion by hepatocytes or due to the obstruction of bile flow through intra-or extra-hepatic bile ducts. This impairment in bile secretion occurs at somewhere between the liver cells (which produce bile) and the duodenum (the first segment of the small intestine). Furthermore, Pruritus is a distressing manifestation of both intrahepatic cholestasis and extrahepatic biliary obstruction. Intrahepatic cholestasis processes associated with pruritus include Primary Biliary Cirrhosis (PBC), cholestasis of pregnancy (pruritus gravidarum), drug-induced cholestasis, and viral hepatitis.
Interestingly, for reasons that are currently unexplained, the severity of pruritus seen in cholestatic conditions has no relationship with the degree of severity of cholestasis, i.e. patients with similar severities of liver disease and cholestasis can have markedly different degrees of pruritus.
Cholestatic Pruritus Market Key Facts
-
As per the Royal College of Obstetricians and Gynaecologists, United Kingdom, obstetric cholestasis is a multifactorial condition of pregnancy characterized by pruritus in the absence of a skin rash with abnormal liver function tests. This condition affects nearly 1% of pregnancies in multiethnic populations in England.
-
A study conducted by Dull and Kremer (2020), chronic pruritus is characteristic of the immune-mediated cholestatic disorders PBC, PSC, and SSC, with a lifetime prevalence of up to 70–80%.
-
Although the data on the prevalence of Cholestatic Pruritus, based on the severity of the disease, is limited; however, certain literature data suggest that 5–10% of patients have severe pruritus refractory to the available medical therapy.
-
Companies across the globe are thoroughly working toward the development of new treatment therapies for Cholestatic Pruritus. Some of the key players in the therapeutic market of cholestatic pruritus at a global level are GlaxoSmithKline, Mirum Pharmaceuticals, Albireo Pharma, Intercept Pharmaceuticals, Cymabay Therapeutics, Care Therapeutics, and others.
-
Some of the emerging therapies in the Cholestatic Pruritus therapeutics market include EP 547, GSK2330672, Seladelpar, Korsuva, LUM001, and others.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Cholestatic Pruritus market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Cholestatic Pruritus market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Cholestatic Pruritus Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
The Report Covers the Cholestatic Pruritus Epidemiology Segmented by –
-
Total Prevalent Population of Cholestatic Pruritus
-
Severity-specific Prevalent Population of Cholestatic Pruritus
-
Gender-specific Prevalent Population of Cholestatic Pruritus
-
Diagnosed and Treatable Population of Cholestatic Pruritus
Cholestatic Pruritus Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cholestatic Pruritus market or expected to get launched during the study period. The analysis covers the Cholestatic Pruritus market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cholestatic Pruritus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Cholestatic Pruritus Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/cholestatic-pruritus-market
Cholestatic Pruritus Therapeutics Analysis
Owing to the launch of upcoming therapies, the Cholestatic Pruritus Therapeutics market size shall increase significantly in the coming years. The emerging drug coming up with the specific mechanism of action is being investigated in patients with Cholestatic Pruritus
Some of the key companies in the Cholestatic Pruritus Therapeutics Market Include
-
Mirum Pharmaceuticals
-
Cara Therapeutics
-
CymaBay Therapeutics
-
GlaxoSmithKline
-
Escient Pharmaceuticals
-
Albireo Pharma
-
Intercept Pharmaceuticals
And many others
Cholestatic Pruritus Therapies Covered in the Report Include:
-
EP 547
-
GSK2330672
-
Seladelpar
-
Korsuva
-
LUM001
And many more
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
https://www.delveinsight.com/sample-request/cholestatic-pruritus-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cholestatic Pruritus Competitive Intelligence Analysis
4. Cholestatic Pruritus Market Overview at a Glance
5. Cholestatic Pruritus Disease Background and Overview
6. Cholestatic Pruritus Patient Journey
7. Cholestatic Pruritus Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Cholestatic Pruritus Treatment Algorithm, Current Treatment, and Medical Practices
9. Cholestatic Pruritus Unmet Needs
10. Key Endpoints of Cholestatic Pruritus Treatment
11. Cholestatic Pruritus Marketed Products
12. Cholestatic Pruritus Emerging Drugs and Latest Therapeutic Advances
13. Cholestatic Pruritus Seven Major Market Analysis
14. Attribute Analysis
15. Cholestatic Pruritus Market Outlook (In US, EU5, and Japan)
16. Cholestatic Pruritus Access and Reimbursement Overview
17. KOL Views on the Cholestatic Pruritus Market
18. Cholestatic Pruritus Market Drivers
19. Cholestatic Pruritus Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/cholestatic-pruritus-market
Other Trending Healthcare Reports By DelveInsight
Cholestatic Pruritus Pipeline Insight
“Cholestatic Pruritus Pipeline Insight, 2022” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Cholestatic Pruritus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/